Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

导出原文传递

翻译打印收藏纠错

作者： Elizabeth Pham ^[1] ; Yin, Melissa ^[2] ; Peters, Christian G. ^[3] ; Lee, Christina R. ; Brown, Donna ; Xu, Ping ; Man, Shan ; Jayaraman, Lata ; Rohde, Ellen ; Chow, Annabelle ; Lazarus, Douglas ; Eliasof, Scott ; Foster, F. Stuart ; Kerbel, Robert S.

作者单位： Cerulean Pharma Inc, Waltham, MA USA ^[1] Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada ^[2] Sunnybrook Res Inst, Biol Sci Platform, 2075 Bayview Ave S217, Toronto, ON M4N 3M5, Canada ^[3]

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer research

2016年76卷15期

4493-4503页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Cancer research

相似文献

Cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Cancer research

相似文献

Cancer research

相关期刊

检索历史清除